Intuitive’s shares fell 2.3% after earnings, a roughly flat reaction that suggests a measured response to the quarter rather than a clear market verdict. Procedure growth and system placements were solid, while the company’s new pricing actions for some high-volume benign procedures are expected to affect financial results.
Shares dropped 11.2% as investors reacted negatively to signs of US procedural growth deceleration and an increasingly cautious outlook amid persistent challenges in China’s market and pricing pressures.
Intuitive delivered a strong Q1 2026 with 17% procedure growth driven by broad-based adoption of da Vinci and Ion systems, despite ongoing challenges in China and Japan.
Intuitive Surgical reported robust performance in Q3 2025, evidenced by 20% worldwide procedure growth and a 23% increase in revenue, driven by strong adoption of the da Vinci V systems.